Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexfadrostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 15/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 9/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fadrozole SCHEMBL3295820 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| S-Fadrozole SCHEMBL13449014 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL25491 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL122801 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL9739941 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL4143 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL4619633 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL1650121 | 0.97 | CYP19A1 (0.95) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2351202 | 0.96 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL23064072 | 0.93 | CYP19A1 (0.86) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120018847-A | Once daily aldosterone synthase inhibitor (R) - (+) -5- (p-cyanophenyl) -5,6,7, 8-tetrahydroimidazo [ L,5-A ] pyridine | 达米安制药股份公司 | 2025-05-16 | — | — | CN | claimed |
| US-20250129071-A1 | ALDOSTERONE SYNTHASE INHIBITOR | DAMIAN PHARMA AG (CH) | 2025-04-24 | — | — | US | claimed |
| US-12202827-B2 | Aldosterone synthase inhibitor | DAMIAN PHARMA AG (CH) | 2025-01-21 | — | — | US | claimed |
| US-20230047158-A1 | ALDOSTERONE SYNTHASE INHIBITOR | DAMIAN PHARMA AG (CH) | 2023-02-16 | — | — | US | claimed |
| US-11447491-B2 | Aldosterone synthase inhibitor | DAMIAN PHARMA AG (CH) | 2022-09-20 | — | — | US | claimed |
| CN-114853755-A | Aldosterone synthase inhibitors | 达米安制药股份公司 | 2022-08-05 | — | — | CN | claimed |
| CN-109890389-B | Aldosterone synthase inhibitors | 达米安制药股份公司 | 2022-07-01 | — | — | CN | claimed |
| US-20260124184-A1 | ONCE DAILY ALDOSTERONE SYNTHASE INHIBITOR (R)-(+)-5-(P-CYANOPHENYL)-5,6,7,8-TETRAHYDROIMIDAZO[L,5-A]PYRIDINE | DAMIAN PHARMA AG (CH) | 2026-05-07 | — | — | US | disclosed |
| CN-120018847-A | Once daily aldosterone synthase inhibitor (R) - (+) -5- (p-cyanophenyl) -5,6,7, 8-tetrahydroimidazo [ L,5-A ] pyridine | 达米安制药股份公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-120018847-A | Once daily aldosterone synthase inhibitor (R) - (+) -5- (p-cyanophenyl) -5,6,7, 8-tetrahydroimidazo [ L,5-A ] pyridine | 达米安制药股份公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250129071-A1 | ALDOSTERONE SYNTHASE INHIBITOR | DAMIAN PHARMA AG (CH) | 2025-04-24 | — | — | US | disclosed |
| WO-2025068686-A1 | TREATMENT FOR BATTEN DISEASE | THE ROYAL VETERINARY COLLEGE (GB) | 2025-04-03 | — | — | WO | disclosed |
| US-12202827-B2 | Aldosterone synthase inhibitor | DAMIAN PHARMA AG (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20070149587-A1 | Valsartan Salts | NOVARTIS AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070149587-A1 | Valsartan Salts | NOVARTIS AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070142475-A1 | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors | SELLNER HOLGER | 2007-06-21 | — | — | US | disclosed |
| US-20070142475-A1 | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors | SELLNER HOLGER | 2007-06-21 | — | — | US | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2005099695-A1 | DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES | NOVARTIS AG (CH) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005089731-A2 | USE OF RENIN INHIBITORS IN THERAPY | NOVARTIS AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | CYP19A1 1/4885CYP11B2 14/4885CYP11B1 5/4885 |
| US-20070149587-A1 | Valsartan Salts | ACE, REN, AGT | CYP19A1 3079/4885CYP11B2 325/4885CYP11B1 584/4885 |
| US-20260124184-A1 | ONCE DAILY ALDOSTERONE SYNTHASE INHIBITOR (R)-(+)-5-(P-CYANOPHENYL)-5,6,7,8-TETRAHYDROIMIDAZO[L,5-A]PYRIDINE | CYP21A2, NR3C2, CYP17A1 | CYP19A1 126/4885CYP11B2 5/4885CYP11B1 4/4885 |
| US-11447491-B2 | Aldosterone synthase inhibitor | CYP21A2, CYP17A1, CYP11B1 | CYP19A1 17/4885CYP11B2 7/4885CYP11B1 3/4885 |
| US-20070142475-A1 | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors | REN, AGTR1, ACE | CYP19A1 1081/4885CYP11B2 911/4885CYP11B1 811/4885 |
| US-20250129071-A1 | ALDOSTERONE SYNTHASE INHIBITOR | CYP21A2, CYP17A1, CYP11B1 | CYP19A1 17/4885CYP11B2 7/4885CYP11B1 3/4885 |
| US-12202827-B2 | Aldosterone synthase inhibitor | CYP21A2, CYP17A1, CYP11B1 | CYP19A1 17/4885CYP11B2 7/4885CYP11B1 3/4885 |
| US-20230047158-A1 | ALDOSTERONE SYNTHASE INHIBITOR | CYP21A2, CYP17A1, CYP11B1 | CYP19A1 17/4885CYP11B2 7/4885CYP11B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.